Loading clinical trials...
Loading clinical trials...
Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III/IV Carcinoma of Anus
Conditions
Interventions
Pembrolizumab
Locations
11
Norway
Oslo University Hospital
Oslo, Norway
Aberdeen Royal Informary
Aberdeen, Scotland, United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Velindre Cancer Centre
Cardiff, United Kingdom
East Suffolk and North Essex NHS Foundation Trust
Colchester, United Kingdom
The Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
Start Date
October 19, 2020
Primary Completion Date
November 30, 2026
Completion Date
November 30, 2026
Last Updated
August 5, 2025
Lead Sponsor
Cardiff University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions